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Background:  Although heart transplant is the ultimate treatment for patients with end-stage heart failure, Left Ventricular Assisted Devices 
(LVADs), when used as a destination therapy, have shown to prolong survival in those who are not candidates for transplant. Little is known 
regarding the impact of its complications on mortality.
methods:  We reviewed the U.S. Food and Drug Administration Manufacturer and User Device Experience (MAUDE) Database from 
January 2013 to July 2014 using the “HeartMate II” key word to identify the reported cases of device malfunction, injury or death. We 
reviewed the event reports and performed a multivariate analysis to identify the association between the LVADs complications and 
mortality. We also plotted the length of time that patients remained on LVAD support until mortality was reported.
results:  Out of a total of 2,160 events reported, 790 (36.5%) were due to mechanical problems, 533 (24.6%) to thromboembolic 
events, 304 (14.0%) to hemolysis, 214 (9.90%) to infections, 204 (9.44%) to hemorrhage, and 115 (5.32%) to other events. Mortality was 
significantly associated with thromboembolic events (OR: 4.09, p<0.0001, CI 2.15 - 7.77) and hemorrhage (OR: 2.75, p<0.0001, CI 1.69 - 
4.47). Survival at 20 and 50 months of LVAD support was 75 and 50% respectively (Figure 1).
conclusion:  The major LVAD complications associated with mortality were thromboembolism and hemorrhage. The data show an 
increase in the survival rate than previously reported.
 
